VICO Therapeutics B.V.
VICO Therapeutics B.V. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at VICO Therapeutics B.V..
VICO Therapeutics B.V. is a company.
Key people at VICO Therapeutics B.V..
Key people at VICO Therapeutics B.V..
Vico Therapeutics B.V. is a clinical-stage genetic medicine company headquartered in Leiden, Netherlands, developing RNA-based antisense oligonucleotide (ASO) therapies to target the root causes of rare genetic neurological diseases.[1][3] Its lead product, VO659, is the first clinical candidate directly targeting CAG repeat expansions—the mutation underlying polyglutamine diseases like Huntington’s disease and spinocerebellar ataxias (SCA1, SCA3)—and is currently in Phase 1/2a trials, with a pipeline also addressing Rett syndrome and familial Alzheimer’s disease.[1][2][3] The company serves patients with severe, underserved neurological disorders by preserving essential protein function while reducing mutant proteins, filling a critical gap in disease-modifying treatments.[1]
Founded in 2019, Vico demonstrates strong growth momentum through its focused pipeline of potential first-in-class medicines and active recruitment of scientists and drug developers, backed by prominent investors like EQT Life Sciences, Kurma Partners, and Droia Ventures.[1][3]
Vico Therapeutics B.V. was founded in 2019 by Luc Dochez, PhD, who serves as Chair of the Board of Directors and brings expertise from Droia Ventures.[1][3] The company emerged from the need for precision therapies in neurology genetics, leveraging innovative ASO platforms to tackle mutations like CAG repeats that cause polyglutamine diseases.[1] Early traction came from developing VO659, which targets the core genetic driver across multiple neurodegenerative conditions, positioning Vico as a clinical-stage player shortly after inception with Phase 1/2a trials underway for SCA and Huntington’s.[3] Pivotal moments include assembling a board with venture leaders from EQT Life Sciences (Martijn Kleijwegt, Felice Verduyn-Van Weegen), Kurma Partners (Remi Droller), and Ackermans & van Haaren (Jeroen Vangindertael, PhD), enabling rapid pipeline advancement.[1]
Vico rides the wave of RNA-targeted genetic medicines, particularly ASOs, which have gained traction post-approvals like Spinraza for SMA, enabling precise editing of genetic drivers in rare diseases.[1] Timing is ideal amid surging investment in neurology genetics, driven by aging populations, better genetic diagnostics, and successes in polyglutamine targeting—market forces favoring Vico’s allele-specific approach for orphan indications with high unmet need.[1][3] By influencing the ecosystem through clinical proof-of-concept in Phase 1/2a, Vico accelerates innovation in neurodegenerative therapies, potentially paving the way for broader ASO applications beyond rare diseases.[2]
Vico’s near-term focus will likely center on topline Phase 1/2a data for VO659, which could validate its platform and trigger partnerships or expansion into late-stage trials across its pipeline.[1][3] Trends like AI-optimized oligonucleotide design and intrathecal delivery advancements will shape progress, amplifying Vico’s edge in precision neurology.[1] Its influence may evolve from niche innovator to ecosystem leader if VO659 succeeds, drawing more capital to CAG-targeted therapies and transforming outcomes for Huntington’s and SCA patients—unlocking the precision genetic targeting it pioneered from day one.[1][2]
